Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Lugaresi

Showing results (21-30 of 201) with videos related to

Pageof 21
Sort By:
Frontiers in Neurology|July 6, 2023
When 'good' is not good enough: a retrospective Rasch analysis study of the Berg Balance Scale for persons with Multiple SclerosisSerena Caselli, Loredana Sabattini, Davide Cattaneo, et al.
Expert Opinion on Drug Delivery|February 25, 2016
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER studyAlessandra Lugaresi, Francesca De Robertis, Marinella Clerico, et al.
Expert Opinion on Drug Delivery|September 16, 2015
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosisMarcello Moccia, Raffaele Palladino, Cinzia Russo, et al.
BMC Neurology|May 4, 2010
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyVirginia Devonshire, Txomin Arbizu, Bjorn Borre, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 11, 2020
Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31Matteo Foschi, Giulia Giannini, Elena Merli, et al.
Journal of Neurology|May 27, 2025
Personalized therapy in multiple sclerosis: an Italian Delphi consensusClaudio Gasperini, Diego Centonze, Antonella Conte, et al.
Multiple Sclerosis and Related Disorders|July 9, 2018
Teeth loss after teriflunomide treatment: Casual or causal? A short case seriesVeria Vacchiano, Nicola Frattaruolo, Luca Mancinelli, et al.
Journal of Neuroimmunology|March 7, 2002
Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosisCarla Iarlori, Marcella Reale, Giovanna De Luca, et al.
Frontiers in Neurology|April 14, 2022
Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic SurveySusan Mohamed, Giovanna Lopane, Loredana Sabattini, et al.
Clinical Neuropharmacology|June 4, 2008
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa studyAlessandra Lugaresi, Valentina Durastanti, Claudio Gasperini, et al.
Pageof 21

Showing results (21-30 of 201) with videos related to

Sort By:
Pageof 21
Frontiers in Neurology|July 6, 2023
When 'good' is not good enough: a retrospective Rasch analysis study of the Berg Balance Scale for persons with Multiple SclerosisSerena Caselli, Loredana Sabattini, Davide Cattaneo, et al.
Expert Opinion on Drug Delivery|February 25, 2016
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER studyAlessandra Lugaresi, Francesca De Robertis, Marinella Clerico, et al.
Expert Opinion on Drug Delivery|September 16, 2015
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosisMarcello Moccia, Raffaele Palladino, Cinzia Russo, et al.
BMC Neurology|May 4, 2010
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyVirginia Devonshire, Txomin Arbizu, Bjorn Borre, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 11, 2020
Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31Matteo Foschi, Giulia Giannini, Elena Merli, et al.
Journal of Neurology|May 27, 2025
Personalized therapy in multiple sclerosis: an Italian Delphi consensusClaudio Gasperini, Diego Centonze, Antonella Conte, et al.
Multiple Sclerosis and Related Disorders|July 9, 2018
Teeth loss after teriflunomide treatment: Casual or causal? A short case seriesVeria Vacchiano, Nicola Frattaruolo, Luca Mancinelli, et al.
Journal of Neuroimmunology|March 7, 2002
Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosisCarla Iarlori, Marcella Reale, Giovanna De Luca, et al.
Frontiers in Neurology|April 14, 2022
Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic SurveySusan Mohamed, Giovanna Lopane, Loredana Sabattini, et al.
Clinical Neuropharmacology|June 4, 2008
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa studyAlessandra Lugaresi, Valentina Durastanti, Claudio Gasperini, et al.
Pageof 21